XML 43 R3.htm IDEA: XBRL DOCUMENT
v3.26.1

Award Timing Disclosure | 12 Months Ended |
--- | --- | ---
Dec. 31, 2025 | Feb. 13, 2025 USD ($) security $ / shares
Award Timing Disclosures [Line Items] |  |
Award Timing MNPI Disclosure | Policies and Practices Related to the Timing of Grants of Certain Equity Awards AbbVie’s policy with respect to its annual equity award for all eligible employees, including the NEOs, is to grant the award and set the grant price, which is used to calculate the number of shares covered by awards and establish the exercise price for stock options, at the compensation committee’s regularly scheduled February meeting each year. These meeting dates generally are the third Thursday of February and are scheduled two years in advance. The grant price is the average of the high and low trading prices of a common share on the date of the grant (rounded up to the next even penny). The grant price for the 2025 annual grant was $192.86. The high, low and closing prices of an AbbVie common share on the grant date (February 13, 2025) were $194.28, $191.43, and $193.45 respectively. All LTI awards are subject to a minimum vesting period of 12 months. ​ The company does not schedule its equity grants in anticipation of the release of material, non-public information (“MNPI”) or time the release of MNPI based on equity grant dates. The following table presents information regarding option awards granted to our NEOs in the fiscal year ended December 31, 2025, during any period beginning four business days before the filing or furnishing of a periodic report or current report disclosing MNPI and ending one business day after the filing or furnishing of such report with the SEC. |
Award Timing Method | AbbVie’s policy with respect to its annual equity award for all eligible employees, including the NEOs, is to grant the award and set the grant price, which is used to calculate the number of shares covered by awards and establish the exercise price for stock options, at the compensation committee’s regularly scheduled February meeting each year. These meeting dates generally are the third Thursday of February and are scheduled two years in advance. The grant price is the average of the high and low trading prices of a common share on the date of the grant (rounded up to the next even penny). The grant price for the 2025 annual grant was $192.86. The high, low and closing prices of an AbbVie common share on the grant date (February 13, 2025) were $194.28, $191.43, and $193.45 respectively. All LTI awards are subject to a minimum vesting period of 12 months. |
Award Timing MNPI Considered | true |
Award Timing, How MNPI Considered | The company does not schedule its equity grants in anticipation of the release of material, non-public information (“MNPI”) or time the release of MNPI based on equity grant dates. |
MNPI Disclosure Timed for Compensation Value | false |
Awards Close in Time to MNPI Disclosures, Table | ​
| ​ ​ ​ |  | ​ ​ ​ |  | ​ ​ ​ |  |  | ​ ​ ​ |  | ​ ​ ​ | Percentage |
|  |  |  |  |  |  |  |  |  |  | change in the |
|  |  |  |  |  |  |  |  |  |  | closing market |
|  |  |  |  |  |  |  |  |  |  | price of the |
|  |  |  |  |  |  |  |  |  |  | securities |
|  |  |  |  |  |  |  |  |  |  | underlying the |
|  |  |  |  |  |  |  |  |  |  | award between |
|  |  |  |  |  |  |  |  |  |  | the trading day |
|  |  |  |  |  |  |  |  |  |  | ending |
|  |  |  |  |  |  |  |  |  |  | immediately |
|  |  |  |  |  |  |  |  |  |  | prior to the |
|  |  |  |  |  |  |  |  |  |  | disclosure of |
|  |  |  |  |  |  |  |  |  |  | material |
|  |  |  |  |  |  |  |  |  |  | nonpublic |
|  |  |  |  |  |  |  |  |  |  | information and |
|  |  |  |  |  |  |  |  |  |  | the trading day |
|  |  |  |  |  |  |  |  |  |  | beginning |
|  |  |  |  |  |  |  |  |  |  | immediately |
|  |  |  |  |  |  |  |  |  |  | following the |
|  |  |  | Number of |  | Exercise |  |  |  | disclosure of |
|  |  |  | securities |  | price of the |  | Grant date fair |  | material |
|  |  |  | underlying the |  | award |  | value of the |  | nonpublic |
Name |  | Grant date |  | award |  | ($/Share) |  | award |  | Information1 |
Robert A. Michael |  | 2/13/2025 |  | 83,333 |  | $ | 192.86 |  | $ 3,199,154 |  | 1.45 | %
Scott T. Reents |  | 2/13/2025 |  | 27,343 |  | $ | 192.86 |  | $ 1,049,698 |  | 1.45 | %
Jeffrey R. Stewart |  | 2/13/2025 |  | 33,854 |  | $ | 192.86 |  | $ 1,299,655 |  | 1.45 | %
Azita Saleki-Gerhardt |  | 2/13/2025 |  | 25,000 |  | $ | 192.86 |  | $ 959,750 |  | 1.45 | %
Roopal B. Thakkar |  | 2/13/2025 |  | 25,000 |  | $ | 192.86 |  | $ 959,750 |  | 1.45 | %
(1) | On February 14, 2025, the company reported its financial results for the fiscal year ended December 31, 2024 on Form 10-K.
Michael |  |
Awards Close in Time to MNPI Disclosures |  |
Name |  | Robert A. Michael
Underlying Securities | security |  | 83,333
Exercise Price | $ / shares |  | $ 192.86
Fair Value as of Grant Date | $ |  | $ 3,199,154
Underlying Security Market Price Change |  | 1.45
Scott T. Reents |  |
Awards Close in Time to MNPI Disclosures |  |
Name |  | Scott T. Reents
Underlying Securities | security |  | 27,343
Exercise Price | $ / shares |  | $ 192.86
Fair Value as of Grant Date | $ |  | $ 1,049,698
Underlying Security Market Price Change |  | 1.45
Jeffrey R. Stewart |  |
Awards Close in Time to MNPI Disclosures |  |
Name |  | Jeffrey R. Stewart
Underlying Securities | security |  | 33,854
Exercise Price | $ / shares |  | $ 192.86
Fair Value as of Grant Date | $ |  | $ 1,299,655
Underlying Security Market Price Change |  | 1.45
Azita Saleki-Gerhardt |  |
Awards Close in Time to MNPI Disclosures |  |
Name |  | Azita Saleki-Gerhardt
Underlying Securities | security |  | 25,000
Exercise Price | $ / shares |  | $ 192.86
Fair Value as of Grant Date | $ |  | $ 959,750
Underlying Security Market Price Change |  | 1.45
Roopal B. Thakkar |  |
Awards Close in Time to MNPI Disclosures |  |
Name |  | Roopal B. Thakkar
Underlying Securities | security |  | 25,000
Exercise Price | $ / shares |  | $ 192.86
Fair Value as of Grant Date | $ |  | $ 959,750
Underlying Security Market Price Change |  | 1.45

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 2 -Subparagraph ii -Sentence D + Details
Name: | ecd_AwardExrcPrice
Namespace Prefix: | ecd_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 2 -Subparagraph ii -Sentence E + Details
Name: | ecd_AwardGrantDateFairValue
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | instant

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 1 + Details
Name: | ecd_AwardTmgDiscLineItems
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 1 + Details
Name: | ecd_AwardTmgHowMnpiCnsdrdTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 1 + Details
Name: | ecd_AwardTmgMethodTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 1 + Details
Name: | ecd_AwardTmgMnpiCnsdrdFlag
Namespace Prefix: | ecd_
Data Type: | xbrli:booleanItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 1 + Details
Name: | ecd_AwardTmgMnpiDiscTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 2 -Subparagraph ii -Sentence C + Details
Name: | ecd_AwardUndrlygSecuritiesAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 2 -Subparagraph ii -Sentence A + Details
Name: | ecd_AwardsCloseToMnpiDiscIndName
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | instant

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 2 + Details
Name: | ecd_AwardsCloseToMnpiDiscTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 2 + Details
Name: | ecd_AwardsCloseToMnpiDiscTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 1 + Details
Name: | ecd_MnpiDiscTimedForCompValFlag
Namespace Prefix: | ecd_
Data Type: | xbrli:booleanItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 2 -Subparagraph ii -Sentence F + Details
Name: | ecd_UndrlygSecurityMktPriceChngPct
Namespace Prefix: | ecd_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | ecd_IndividualAxis=abbv_MichaelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=abbv_ScottT.ReentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=abbv_JeffreyR.StewartMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=abbv_AzitaSalekiGerhardtMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=abbv_RoopalB.ThakkarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |